Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Committee On Brain Tumor Endpoints Planned For Summer – Pazdur

Executive Summary

FDA's Oncologic Drugs Advisory Committee could meet as soon as summer or early fall to discuss appropriate clinical trial endpoints for primary brain tumors, Office of Oncology Drug Products Director Richard Pazdur said Jan. 27 in an interview with "The Pink Sheet.

You may also be interested in...



Progression-Free Survival Is Meaningful Endpoint For Glioma Trials

Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed

Progression-Free Survival Is Meaningful Endpoint For Glioma Trials

Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed

Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar

Pfizer's newly approved oncologic Sutent will have a dosing advantage and will be priced at a slight discount compared to Bayer/Onyx' Nexavar

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel